News

Significant increases in macular and choroidal thickness were observed in the fovea and perifovea at all postoperative visits in patients with diabetic retinopathy.

Positive topline results from the phase 2 trial indicate EYP-1901 exhibited statistical non-inferiority in BCVA to aflibercept, with a favorable safety profile.

Results from a systematic review highlighted the clinical need for specific biomarkers for PAD and the viability of noninvasive ophthalmic imaging techniques for diagnosis.

A substudy of the ASCEND trial offers insight into the effects of omega-3 fatty acids use on risk of diabetic retinopathy in people with diabetes.

In a new study, inserting the XEN-45 implant in patients with uncontrolled uveititc glaucoma prevented conventional glaucoma surgery in 83.3% of patients.

Investigators observed differences in choroidal and inner neural layers among patients previously infected with COVID-19 compared to healthy controls.

A systematic review and meta-analysis provides insight into the potential for increased risk of noninfectious uveitis among people with vitamin D deficiency.

Pinkerton reflects on the breakthrough approval for the non-estrogen, non-hormonal daily oral drug earlier this year.

The review emphasized the importance of therapies that provide sustained visual outcomes, given the increasing incidence of nAMD among aging adults.

A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.

The final quarterly issue of the year touches on head-to-head trial data, a new treatment for erosive esophagitis, an ulcerative colitis agent, and the latest ACG recommendations for Celiac disease.e.

An expert reviews the updated recommendations of the American College of Gastroenterology guidelines on the evaluation and management of celiac disease.

While more studies are needed to ensure the safety of long-term therapy with PCABs, this study establishes a role for the use of vonoprazan in the healing and maintenance of healing in patients with erosive esophagitis.

Ustekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.

The S1PR modulators are currently positioned to serve as a great treatment option for patients with moderate disease who are hesitant to escalate to a biologic treatment.

The approval was based on data from the APPLY-PNH trial and APPOINT-PNH study, which showed iptacopan was superior for hemoglobin improvement in the absence of red blood cell transfusions and in transfusion avoidance rate compared to patients who stayed on anti-C5 treatments.

An overview of the journey and significant events of 2023 that have catapulted semaglutide from a type 2 diabetes agent to the topic of discussions among circles across healthcare and beyond.

The guideline was developed by a multidisciplinary panel and consists of 11 conditional recommendations for the use of biomarkers in the management of Crohn disease.

Just more than a month after the FDA approved their first biosimilar to ustekinumab (Stelara), Bio-Thera Solutions announced positive results from their phase 3 trial of BAT2206

Real-world data shows extended intervals with both brolucizumab alone or alternating anti-VEGF treatment regimens after 12 and 18 months in nAMD eyes.

These results in the subgroup analysis, seen among individuals who were both identified as Asian and non-Asian, align with data published previously in the overall population.

In an interview with HCPLive, Juliana Reed, MS, explains the pivotal role biosimilars play in healthcare and the barriers to access and adoption.

This new analysis on IBD patients initiating biologic therapy with the biosimilar ABP 501 indicates that the drug’s lower cost and efficacy may lead to greater use.

Pharmacokinetic exposure of the biosimilar insulin and reference product showed similarity, supporting the interchangeability between the two insulin aspart products.

The biosimilars month in review highlights top data demonstrating the efficacy of biosimilars for treating inflammatory bowel disease and plaque psoriasis, as well as trends in adopting biosimilars among patients and clinicians in the US.

A single-center cohort analysis showed the biosimilar provided similar PBSC mobilization to originator filgrastim.

There was no statistically significant difference in postoperative thromboembolic events and incident heparin-induced thrombocytopenia among patients treated with branded versus biosimilar enoxaparin.

Aotearoa, New Zealand had a mandatory adalimumab biosimilar transition from March – September 2022. A survey reveals low satisfaction with biosimilar’s quality, as well as the lack of alcoholic wipes and a support program.